General pathways and personalized risk of morbidity after sepsis
脓毒症后发病的一般途径和个性化风险
基本信息
- 批准号:8950589
- 负责人:
- 金额:$ 19.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-15 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAcute Kidney FailureAdultAmericanAwardBig DataBiometryCaringCatalogingCatalogsCessation of lifeChargeChronicChronic DiseaseChronic Obstructive Airway DiseaseClinical DataClinical ManagementClinical ResearchCohort StudiesCritical CareCritical IllnessDataDevelopmentDiagnosisDiseaseDoctor of PhilosophyEnsureEnvironmentEpidemicEpidemiologyFaceFailureFoundationsGoalsHealthHealthcareHeart failureHeatingHospitalizationHospitalsImpaired cognitionIncidenceIndividualInfectionInflammationInpatientsInterventionLaboratoriesLeadLeftLiteratureLogistic RegressionsLungMapsMedicareMental DepressionMentorsMethodologyMichiganModelingMorbidity - disease rateOutcomeOutpatientsPathway interactionsPatient CarePatient riskPatientsPhasePhysiciansPhysiologicalPopulationProceduresProcessProductivityPublic HealthPulmonary InflammationQuality of lifeRecoveryRecurrenceRehabilitation therapyRelative (related person)ResearchResearch DesignResearch PersonnelRiskSamplingScienceScientistSepsisSiteStatistical MethodsStatistical ModelsSterilitySurvivorsSystemTechniquesTestingTimeTrainingUniversitiesVeteransWorkadverse outcomebeneficiarycareercareer developmentclinical epidemiologyclinically relevantexperienceforesthealth administrationimplementation scienceimprovedinnovationmodel buildingmortalitypersonalized medicinepredictive modelingpreventskillstoolusability
项目摘要
DESCRIPTION (provided by applicant): This K08 proposal will complete Hallie Prescott, MD; MSc's training towards her long-term career goal of improving the long-term survival and quality of life of critical illness survivors. Dr. Prescott is a pulmonary & critical care physician and scientist at the University of Michigan, with Master's training in clinical study design and biostatistics. This proposal builds on Dr. Prescott's prior experience, leveraging advanced statistical methods, granular clinical data, and the rich training environment at University of Michigan to improve our understanding and management of post-sepsis morbidity. The research will be completed under the guidance of primary mentor Theodore J. Iwashyna, MD, PhD, co-mentor Kenneth Langa, MD, PhD, and co-mentor Richard Gonzalez, PhD, with a planned mentor-the-mentor strategy and additional input from an advisory board of physician-scientists. This 5-year plan includes formal coursework, professional development, and mentored research, with defined milestones to ensure productivity and a successful transition to independence. This mentored research has 2 specific Scientific Aims: AIM 1: Test the relative importance 3 competing hypotheses for the general pathway of post- sepsis morbidity. * AIM 2: Develop a diagnosis-specific readmission risk profile tool to personalize treatment for severe sepsis survivors in the immediate (90-day) post-hospital setting. Inherent to completing these high-level Aims, Dr. Prescott will also (1) characterize the epidemiology of multi- morbidity and hospitalization in severe sepsis survivors, (2) identify the health conditions most increased after
severe sepsis, (3) define the incremental benefits of specific clinical data in improving risk prediction, (4) compare the accuracy and usability of complementary cutting edge personalized prediction methodologies. This work will build to at least two R01 proposals: (1) to examine the mechanism by which a specific chronic health condition is increased after severe sepsis (as identified in Aim 1) or to examine how post-sepsis morbidity differs from that of less-severe infections and sterile inflammation, and (2) to implement and evaluate the diagnosis-specific risk profile tool developed in Aim 2. Beyond establishing the foundation for a programmatic line of research to improve the care of severe sepsis survivors, this proposal will provide Dr. Prescott with research skills that are readily applicable to additional domains of critical illness research In short, this K08 award will support and accelerate the career development activities of Dr. Prescott and allow her to successfully launch into the next phase of her career as an independent investigator.
描述(由申请提供):该K08提案将完成医学博士Hallie Prescott; MSC培训她的长期职业目标是改善重症疾病生存的长期生存和生活质量。普雷斯科特(Prescott)博士是密歇根大学的一名肺和重症监护身体和科学家,并在临床研究设计和生物统计学方面接受了硕士学位。这项建议是基于普雷斯科特博士先前的经验,利用高级统计方法,颗粒状临床数据以及密歇根大学的丰富培训环境,以提高我们对塞普斯后发病率的理解和管理。这项研究将在主要导师Theodore J. Iwashyna,医学博士,博士的指导下完成,博士肯尼斯·兰加(Kenneth Langa)和博士学位,并获得了计划中的导师策略,并获得了实体主义者顾问委员会的其他投入。这项为期5年的计划包括正式的课程,专业发展和心理研究,并具有确定的里程碑,以确保生产力和成功过渡到独立性。这项修改的研究具有2个特定的科学目的:目标1:测试相对重要性3竞争性假设对败血后发病率的一般途径。 * AIM 2:开发一种特定于诊断的再入院风险概况工具,以在院后立即(90天)的情况下个性化严重败血症生存的治疗方法。 Prescott博士还将(1)固有这些高级目标,(1)在严重的败血症生存中的多种多物种和住院的流行病学,(2)确定后的健康状况最大
严重的败血症,(3)定义了特定临床数据在改善风险预测方面的增量益处,(4)比较互补尖端的个性化预测方法的准确性和可用性。这项工作将至少提高两个R01提案:(1)检查在严重的败血症后提高特定慢性健康状况的机制(AIM 1中所述)或研究隔离后的发病率如何与较小的参与者感染和无菌感染相差,以及(2)实施和评估诊断性的临床范围2),超出了诊断的临床范围。该提案对严重的败血症生存的照顾,将为Prescott博士提供研究技能,很容易适用于重症疾病研究的其他领域,该K08奖将支持和加速Prescott博士的职业发展活动,并允许她成功地进入职业生涯的下一个独立研究员。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hallie Christine Prescott其他文献
Hallie Christine Prescott的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hallie Christine Prescott', 18)}}的其他基金
Optimizing Veteran Recovery from Sepsis (OVeR-Sepsis)
优化脓毒症退伍军人康复 (OVeR-脓毒症)
- 批准号:
10311252 - 财政年份:2021
- 资助金额:
$ 19.43万 - 项目类别:
Optimizing Veteran Recovery from Sepsis (OVeR-Sepsis)
优化脓毒症退伍军人康复 (OVeR-脓毒症)
- 批准号:
10496554 - 财政年份:2021
- 资助金额:
$ 19.43万 - 项目类别:
Benchmarking Hospital Quality: Template Matching versus Conventional Regression Approaches
医院质量基准测试:模板匹配与传统回归方法
- 批准号:
10308540 - 财政年份:2018
- 资助金额:
$ 19.43万 - 项目类别:
Benchmarking Hospital Quality: Template Matching versus Conventional Regression Approaches
医院质量基准测试:模板匹配与传统回归方法
- 批准号:
9679239 - 财政年份:2018
- 资助金额:
$ 19.43万 - 项目类别:
Benchmarking Hospital Quality: Template Matching versus Conventional Regression Approaches
医院质量基准测试:模板匹配与传统回归方法
- 批准号:
10186545 - 财政年份:2018
- 资助金额:
$ 19.43万 - 项目类别:
General pathways and personalized risk of morbidity after sepsis
脓毒症后发病的一般途径和个性化风险
- 批准号:
9124922 - 财政年份:2015
- 资助金额:
$ 19.43万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
- 批准号:22304039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
- 批准号:82360957
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:地区科学基金项目
相似海外基金
Shifting paradigms to emerging toxins in freshwater cyanobacterial blooms
淡水蓝藻水华中新出现的毒素的范式转变
- 批准号:
10912318 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别:
Enhancing Research capacity for Sickle Cell Disease and related NCDs across the Lifespan in Uganda. ''Enrich Project''
加强乌干达全生命周期镰状细胞病和相关非传染性疾病的研究能力。
- 批准号:
10665128 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别:
Leveraging a novel health records platform to predict the development of cardiovascular disease following kidney transplantation
利用新型健康记录平台预测肾移植后心血管疾病的发展
- 批准号:
10679322 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别:
Neural and Renal Contributions to Hypertension with Androgen Deprivation Therapy
雄激素剥夺疗法对高血压的神经和肾脏影响
- 批准号:
10662133 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别:
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.
用于抗体介导的移植物排斥反应的 II 类人类白细胞抗原生物制剂。
- 批准号:
10598931 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别: